Volume 6, Issue 1 (Avicenna Journal of Pharmaceutical Research, Jun 2025)
Avicenna J Pharma Res 2025, 6(1): 78-80 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Emami S, Ghalandari N. Management of Chorea-Athetosis-Dystonia in a 67-Year-Old Male with Acute Myeloid Leukemia (AML) and Parkinson’s Disease on Levodopa Therapy. , Avicenna J Pharma Res. 2025; 6 (1) :78-80
URL: http://ajpr.umsha.ac.ir/article-1-114-en.html
URL: http://ajpr.umsha.ac.ir/article-1-114-en.html
1- Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran & Medicinal Plants and Natural Products Research Center, Institute of Cancer, Hamadan University of Medical Sciences, Hamadan, Iran
2- Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran & Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
2- Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran & Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract: (16 Views)
Background: Managing overlapping movement disorders in patients with hematologic malignancies is challenging, and levodopa-induced dyskinesias can complicate treatment of comorbid Parkinson’s disease.
Methods: Case report of a 67-year-old man with newly diagnosed AML who developed chorea, athetosis, and dystonia while receiving levodopa for comorbid Parkinson’s disease. Tetrabenazine was initiated for symptomatic control of the hyperkinetic movements.
Results: Tetrabenazine led to substantial clinical improvement in the hyperkinetic movements, with acceptable tolerability despite the potential dopaminergic interactions.
Conclusion: This case highlights the challenges of managing overlapping movement disorders in patients with hematologic malignancies and suggests that tetrabenazine may be a therapeutic option for levodopa-induced dyskinesias.
Methods: Case report of a 67-year-old man with newly diagnosed AML who developed chorea, athetosis, and dystonia while receiving levodopa for comorbid Parkinson’s disease. Tetrabenazine was initiated for symptomatic control of the hyperkinetic movements.
Results: Tetrabenazine led to substantial clinical improvement in the hyperkinetic movements, with acceptable tolerability despite the potential dopaminergic interactions.
Conclusion: This case highlights the challenges of managing overlapping movement disorders in patients with hematologic malignancies and suggests that tetrabenazine may be a therapeutic option for levodopa-induced dyskinesias.
Type of Study: case report |
Subject:
Special
Received: 2026/10/31 | Accepted: 2025/09/1 | Published: 2026/10/31
Received: 2026/10/31 | Accepted: 2025/09/1 | Published: 2026/10/31
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
